Anil Khubchandani appointed as MD, CEO of Sekhmet Pharmaventures

May 29, 2023 09:45 pm | Updated 10:40 pm IST - MUMBAI

A private equity consortium led by PAG, an Asia-based investment firm, has appointed Anil Khubchandani as Managing Director and CEO of Sekhmet Pharmaventures Pvt. Ltd., an investment platform established to nurture and grow India’s next generation of active pharmaceutical ingredient (API) companies.

 Mr. Khubchandani in his most recent role, had served as Co-CEO and Whole-time Director of Jubilant Ingrevia Ltd., an integrated provider of life science ingredients and specialty chemicals.

Sekhmet Pharmaventures is the India arm of Gamot API Pte. Ltd., a Singapore-based platform launched by PAG along with Indian private equity firms CX Partners and Samara Capital to buy stakes in fast-growing pharma companies.

 The platform acquired control of Chennai-based Anjan Drug Pvt. Ltd. in October 2020 and the Hyderabad-based Optimus Drugs group of companies in September 2022.

 Gamot API is majority owned by PAG, which has invested over $1.5 billion in India across its private equity and private debt businesses.

Nikhil Srivastava, Partner and Managing Director, Head of India Private Equity for PAG said, “Anil is a seasoned executive who brings a demonstrated track record of excellence in the life sciences ingredients industry and a wide range of experience across technical, commercial, and managerial roles.”

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.